Related Experiment Video
Updated: Feb 10, 2026

Examining BCL-2 Family Function with Large Unilamellar Vesicles
Published on: October 5, 2012
The dietary compound luteolin inhibits pancreatic cancer growth by targeting BCL-2
Zhimei Li1, Yiyuan Zhang, Lixia Chen
1Hubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. li_hua@hust.edu.cn.
Abstract:
Overexpression of the prosurvival protein BCL-2 contributes to malignant cell initiation, progression and resistance to treatment. Agents that function as its natural antagonists targeting BCL-2 must provide therapeutic benefit. In SW1990 pancreatic cancer cells, amplified BCL-2 was observed, which was believed to offer advantages for malignant cell survival and lead to poor patient outcome. Using structure-based virtual ligand screening, luteolin was found to be a natural small-molecule inhibitor of BCL-2, which exhibited dose-response proapoptosis activity in a BCL-2 dependent manner in vitro. The cellular thermal shift assay (CETSA) and notably competitive binding assay by the microscale thermophoresis (MST) method provided the evidence that this flavonoid directly bound to BCL-2. Mechanistic studies revealed that luteolin (compound 1) displaced BAX from the hydrophobic cleft of BCL-2, allowing mitochondrial permeabilization, and inducing SW1990 cancer cells to die. Meanwhile, luteolin represented significant tumor growth inhibition in an SW1990 xenograft model. Collectively, luteolin is rationally proved to trigger SW1990 cells to apoptosis by targeting BCL-2, and may serve as a potential agent for this cancer therapy.
Insights
Luteolin, a natural compound, directly targets and inhibits the BCL-2 protein in pancreatic cancer cells. This inhibition triggers apoptosis and reduces tumor growth, suggesting potential as a novel cancer therapy.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Research
Background:
- Overexpression of the BCL-2 protein promotes cancer cell survival and treatment resistance.
- BCL-2 is amplified in SW1990 pancreatic cancer cells, correlating with poor patient outcomes.
- Targeting BCL-2 with natural antagonists offers potential therapeutic benefits.
Purpose of the Study:
- To identify natural small-molecule inhibitors of BCL-2.
- To investigate the therapeutic potential of luteolin in pancreatic cancer.
- To elucidate the mechanism by which luteolin induces cancer cell death.
Main Methods:
- Structure-based virtual ligand screening identified luteolin as a BCL-2 inhibitor.
- Cellular thermal shift assay (CETSA) and microscale thermophoresis (MST) confirmed direct binding of luteolin to BCL-2.
- In vitro proapoptotic assays and in vivo xenograft models assessed luteolin's efficacy.
Main Results:
- Luteolin demonstrated dose-dependent, BCL-2-mediated proapoptotic activity in SW1990 cells.
- Luteolin directly binds to BCL-2, displacing BAX and inducing mitochondrial permeabilization.
- Luteolin significantly inhibited tumor growth in a SW1990 xenograft mouse model.
Conclusions:
- Luteolin effectively triggers apoptosis in SW1990 pancreatic cancer cells by targeting BCL-2.
- Luteolin's mechanism involves direct binding to BCL-2, leading to BAX displacement and cell death.
- Luteolin shows promise as a potential therapeutic agent for pancreatic cancer.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Dietary Connections
Feedback Inhibition
Proteins: Dietary Sources and Requirements
Molecules and Compounds
Organic Compounds

